Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
ITGAL Antibody (Center) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | P20701 |
|---|---|
| Clone Names | 100427017 |
| Gene ID | 3683 |
|---|---|
| Other Names | Integrin alpha-L, CD11 antigen-like family member A, Leukocyte adhesion glycoprotein LFA-1 alpha chain, LFA-1A, Leukocyte function-associated molecule 1 alpha chain, CD11a, ITGAL, CD11A |
| Target/Specificity | The synthetic peptide sequence used to generate the antibody AP13692c was selected from the Center region of ITGAL. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | ITGAL (HGNC:6148) |
|---|---|
| Synonyms | CD11A |
| Function | Integrin ITGAL/ITGB2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrin ITGAL/ITGB2 is a receptor for F11R (PubMed:11812992, PubMed:15528364). Integrin ITGAL/ITGB2 is a receptor for the secreted form of ubiquitin-like protein ISG15; the interaction is mediated by ITGAL (PubMed:29100055). Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity (PubMed:15356110). Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils (PubMed:11812992). Required for generation of common lymphoid progenitor cells in bone marrow, indicating a role in lymphopoiesis (By similarity). Integrin ITGAL/ITGB2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages (PubMed:23775590). |
| Cellular Location | Cell membrane; Single-pass type I membrane protein |
| Tissue Location | Leukocytes. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
ITGAL encodes the integrin alpha L chain. Integrins areheterodimeric integral membrane proteins composed of an alpha chainand a beta chain. This I-domain containing alpha integrin combineswith the beta 2 chain (ITGB2) to form the integrin lymphocytefunction-associated antigen-1 (LFA-1), which is expressed on allleukocytes. LFA-1 plays a central role in leukocyte intercellularadhesion through interactions with its ligands, ICAMs 1-3(intercellular adhesion molecules 1 through 3), and also functionsin lymphocyte costimulatory signaling. Two transcript variantsencoding different isoforms have been found for this gene.
References
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Kuwano, Y., et al. Blood 116(4):617-624(2010)Ghannam, S., et al. J. Immunol. 185(1):302-312(2010)Quist, S.R., et al. Acta Derm. Venereol. 90(4):429-430(2010)Lipkin, S.M., et al. Cancer Prev Res (Phila) 3(5):597-603(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
